Hess GP, Natarajan P, Faridi KF, Fievitz A, Valsdottir L, Yeh RW. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. Circulation. 2017;136(23):2210-2219. doi:10.1161/CIRCULATIONAHA.117.028430
Musunuru K, Kathiresan S. Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis. Circ Res. 2016;118(4):579-85. doi:10.1161/CIRCRESAHA.115.306398